DGS Capital Management LLC Takes Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

DGS Capital Management LLC bought a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the fourth quarter, Holdings Channel reports. The institutional investor bought 11,419 shares of the specialty pharmaceutical company’s stock, valued at approximately $60,000.

A number of other institutional investors have also modified their holdings of the business. State of Tennessee Treasury Department increased its holdings in shares of Eagle Pharmaceuticals by 4.1% in the 4th quarter. State of Tennessee Treasury Department now owns 8,345 shares of the specialty pharmaceutical company’s stock valued at $244,000 after acquiring an additional 328 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 8.6% in the 4th quarter. Lazard Asset Management LLC now owns 4,703 shares of the specialty pharmaceutical company’s stock valued at $137,000 after acquiring an additional 373 shares during the period. Legal & General Group Plc increased its holdings in shares of Eagle Pharmaceuticals by 1.5% in the 4th quarter. Legal & General Group Plc now owns 26,857 shares of the specialty pharmaceutical company’s stock valued at $785,000 after acquiring an additional 400 shares during the period. Credit Suisse AG increased its holdings in shares of Eagle Pharmaceuticals by 4.3% in the 2nd quarter. Credit Suisse AG now owns 13,514 shares of the specialty pharmaceutical company’s stock valued at $263,000 after acquiring an additional 557 shares during the period. Finally, Great West Life Assurance Co. Can increased its holdings in shares of Eagle Pharmaceuticals by 7.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 10,180 shares of the specialty pharmaceutical company’s stock valued at $517,000 after acquiring an additional 686 shares during the period. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Price Performance

Shares of Eagle Pharmaceuticals stock opened at $4.39 on Thursday. The stock has a market capitalization of $57.03 million, a price-to-earnings ratio of 3.72 and a beta of 0.41. The firm’s fifty day simple moving average is $5.54 and its 200-day simple moving average is $7.37. Eagle Pharmaceuticals, Inc. has a 12 month low of $4.10 and a 12 month high of $30.40.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.